FDA advisers back Moderna’s 50+ flu shot on Thursday, tilting chances for first mRNA seasonal bid
A key FDA advisory panel says Moderna’s benefits outweigh risks, giving its mRNA flu vaccine a regulatory momentum boost.
By Mohammed Al-Shehri·· 3 min
2 briefings · “mRNA”
A key FDA advisory panel says Moderna’s benefits outweigh risks, giving its mRNA flu vaccine a regulatory momentum boost.
A February refusal to review unraveled into a unanimous VRBPAC vote and fresh data on efficacy, immunogenicity, and safety.